Investigational drug · Phase 2
VS-7375
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for G12D Mutated KRAS, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma (PDAC).
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
4
4 still active
All registered trials
4
Any phase or sponsor naming "VS-7375"
First trial start
2025
Jun 24, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "VS-7375", any sponsor or status.
Conditions studied
As listed on its trial records.
- G12D Mutated KRAS
- Colorectal Cancer
- Pancreatic Ductal Adenocarcinoma (PDAC)
- Pancreatic Ductal Adenocarcinoma
- Non Small Cell Lung Cancer
- Solid Tumor, Adult
- Non-Small Cell Lung Cancer
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Colorectal cancer · Pancreatic cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "VS-7375" as an intervention, largest first.
Verastem, Inc.Industry
NCT07020221 · 616 participants (planned) · Start Jun 24, 2025 · Primary completion Dec 2028
Drug: VS-7375; Cetuximab and 6 more · For: Pancreatic Ductal Adenocarcinoma; Non Small Cell Lung Cancer; Colorectal Cancer and 2 more
Sites: Los Angeles, California; Baltimore, Maryland; Boston, Massachusetts · 22 sites in all
- A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic CancerPivotal-lookingRecruiting
Verastem, Inc.Industry
NCT07644559 · 185 participants (planned) · Start Jun 16, 2026 · Primary completion Jun 2027
Drug: VS-7375; cetuximab (or panitumumab if α-gal IgE+ or cetuximab reaction) · For: Pancreatic Ductal Adenocarcinoma (PDAC); G12D Mutated KRAS
Sites: Los Angeles, California; Coral Springs, Florida; Jacksonville, Florida · 38 sites in all
- A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal CancerPivotal-lookingRecruiting
Verastem, Inc.Industry
NCT07659795 · 150 participants (planned) · Start Jul 28, 2026 · Primary completion Jun 2027
Drug: VS-7375; cetuximab and 2 more · For: Colorectal Cancer
Sites: Scottsdale, Arizona; Los Angeles, California; Coral Springs, Florida · 35 sites in all
- A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung CancerPivotal-lookingRecruiting
Verastem, Inc.Industry
NCT07659782 · 105 participants (planned) · Start Jul 22, 2026 · Primary completion Jun 2027
Drug: VS-7375 · For: Non-Small Cell Lung Cancer
Sites: Scottsdale, Arizona; Los Angeles, California; Aurora, Colorado · 26 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- KRAS in pancreatic cancer: from molecular biology to transformative therapeutics.
Abdelhakeem A, Ganatra N, Gul K, et al. · J Hematol Oncol 2026
- Emerging Therapeutic Strategies for Non-G12C KRAS Mutations in Colorectal Cancer: Focusing on G12D and G12V.
Sagawa T, Hirakawa M, Nagashima H, et al. · J Gastrointest Cancer 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.